Vericel Corporation (VCEL) and Its Competitors Financial Contrast
Vericel Corporation (NASDAQ: VCEL) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its competitors? We will compare Vericel Corporation to similar companies based on the strength of its profitability, dividends, earnings, institutional ownership, risk, analyst recommendations and valuation.
This table compares Vericel Corporation and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Vericel Corporation Competitors||-13,141.50%||229.97%||-23.09%|
Earnings & Valuation
This table compares Vericel Corporation and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Vericel Corporation||$53.77 million||-$20.03 million||-4.09|
|Vericel Corporation Competitors||$578.59 million||$241.91 million||-6.25|
Vericel Corporation’s competitors have higher revenue and earnings than Vericel Corporation. Vericel Corporation is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
33.9% of Vericel Corporation shares are owned by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 3.3% of Vericel Corporation shares are owned by insiders. Comparatively, 13.9% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and recommmendations for Vericel Corporation and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Vericel Corporation Competitors||190||906||1678||67||2.57|
Vericel Corporation presently has a consensus target price of $6.33, indicating a potential upside of 40.74%. As a group, “Biopharmaceuticals” companies have a potential downside of 1.60%. Given Vericel Corporation’s stronger consensus rating and higher probable upside, equities analysts clearly believe Vericel Corporation is more favorable than its competitors.
Risk and Volatility
Vericel Corporation has a beta of 3.07, meaning that its share price is 207% more volatile than the S&P 500. Comparatively, Vericel Corporation’s competitors have a beta of 1.24, meaning that their average share price is 24% more volatile than the S&P 500.
Vericel Corporation competitors beat Vericel Corporation on 7 of the 12 factors compared.
About Vericel Corporation
Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.
Receive News & Stock Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related stocks with our FREE daily email newsletter.